1. Home
  2. EDAP vs NKTX Comparison

EDAP vs NKTX Comparison

Compare EDAP & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$3.41

Market Cap

163.4M

Sector

Health Care

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.29

Market Cap

168.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDAP
NKTX
Founded
1979
2015
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.4M
168.2M
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
EDAP
NKTX
Price
$3.41
$2.29
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$2.00
$11.33
AVG Volume (30 Days)
39.8K
539.7K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
$70,527,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.63
N/A
52 Week Low
$1.21
$1.48
52 Week High
$5.05
$2.81

Technical Indicators

Market Signals
Indicator
EDAP
NKTX
Relative Strength Index (RSI) 36.24 52.12
Support Level $1.98 $1.95
Resistance Level $3.44 $2.32
Average True Range (ATR) 0.34 0.13
MACD -0.03 0.02
Stochastic Oscillator 29.35 70.97

Price Performance

Historical Comparison
EDAP
NKTX

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: